Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by RebrAIn
RebrAIn Receives Second FDA 510(k) Clearance to Optimize Targeting in Stereotactic and Functional Neurosurgery for Both Deep Brain Stimulation and Lesioning Techniques (MRgFUS and Radiosurgery)
August 30, 2024
From
RebrAIn
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.